<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Saudi J Gastroenterol</journal-id>
      <journal-id journal-id-type="publisher-id">SJG</journal-id>
      <journal-title-group>
        <journal-title>Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1319-3767</issn>
      <issn pub-type="epub">1998-4049</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21912063</article-id>
      <article-id pub-id-type="pmc">3178924</article-id>
      <article-id pub-id-type="publisher-id">SJG-17-348</article-id>
      <article-id pub-id-type="doi">10.4103/1319-3767.84494</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Concurrent Autoimmune Hepatitis and Grave's Disease in Hepatitis C during Pegylated Interferon &#x3B1;-2a and Ribavirin Therapy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Trikudanathan</surname>
            <given-names>Guru V.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ahmad</surname>
            <given-names>Imad</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Israel</surname>
            <given-names>Jonathan L</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Internal Medicine, University of Connecticut Medical Center, Farmington, USA</aff>
      <aff id="aff2"><label>1</label>Division of Gastroenterology, Hartford Hospital, Hartford, CT, USA</aff>
      <author-notes>
        <corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Jonathan Israel, Division of Gastroenterology, Hartford Hospital, 85 Seymour Street, Suite 1000, CT-06106, USA. E-mail: <email xlink:href="jisrael@connecticutgi.org">jisrael@connecticutgi.org</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2011</year>
      </pub-date>
      <volume>17</volume>
      <issue>5</issue>
      <fpage>348</fpage>
      <lpage>352</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>6</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>9</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Saudi Journal of Gastroenterology</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Classical interferon-&#x3B1; has been shown to be associated with the development of a variety of autoimmune disorders. A 34-year-old white woman with chronic hepatitis C virus infection who was treated with pegylated interferon &#x3B1;-2a and ribavirin, developed Grave's disease and autoimmune hepatitis (AIH) at 32 and 44 weeks, respectively, following initiation of the therapy. The diagnosis of AIH was made based on the new development of anti-smooth muscle antibodies, anti-mitochondrial antibodies, and liver biopsy findings. It was confirmed by positive response to steroid challenge and was assessed according to the international AIH scoring system. Based on the previous case reports, we review the existing literature. Clinicians should be aware of the possibility of multiple autoimmune disorders during interferon-based therapy for chronic hepatitis.</p>
      </abstract>
      <kwd-group>
        <kwd>Autoimmune hepatitis</kwd>
        <kwd>Grave's disease</kwd>
        <kwd>hepatitis C</kwd>
        <kwd>interferon</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Currently, a combination therapy with pegylated interferon (PEG-IFN) and ribavirin is being widely used for the treatment of chronic hepatitis C (CHC). We hereby describe a case of concurrent onset of autoimmune hepatitis (AIH) and Grave's disease during this therapy, via the autoimmune process. These findings suggest that clinicians should be conscious of the possible development of multiple autoimmune diseases during a combination therapy for CHC.</p>
    <sec sec-type="cases" id="sec1-1">
      <title>CASE REPORT</title>
      <p>A 34-year-old Caucasian woman, an active smoker with a history of vaginal lichen sclerosus, was evaluated for symptoms of fatigue. She denied alcohol, intravenous drug abuse, or blood transfusions and was in a monogamous relationship.</p>
      <p>Workup revealed hepatitis C genotype 1b virus with a viral load of 5720 IU/mL. Her pretreatment alanine transaminase (ALT) and aspartate transaminase (AST) were 72 and 74 U/L, with liver biopsy demonstrating mild inflammation in the liver and minimal fibrosis [<xref ref-type="fig" rid="F1">Figure 1</xref>; <xref ref-type="table" rid="T1">Table 1</xref>].</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Pretreatment liver biopsy showing mild inflammation and minimal fibrosis</p>
        </caption>
        <graphic xlink:href="SJG-17-348-g001"/>
      </fig>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Laboratory findings at presentation</p>
        </caption>
        <graphic xlink:href="SJG-17-348-g002"/>
      </table-wrap>
      <p>The patient had normal thyroid function tests prior to initiating therapy with 180 &#x3BC;g of PEG-IFN weekly and 400 mg of ribavirin twice daily. She had a rapid virologic response with her viral load reaching below 5 IU/mL within a month. After 32 weeks of treatment, she developed palpitations, tremors, weight loss, and insomnia. Laboratory evaluation revealed that thyroid stimulating hormone was suppressed at 0.02 &#x3BC;IU/mL; free T3 and free T4 were elevated at 1007pg/dL and 3.45ng/dL, respectively. There was a diffuse and intense homogenous Iodine-123 uptake by the thyroid. In spite of negative thyroid stimulating immunoglobin (TSI) antibodies, the presence of typical clinical manifestations along with the diffuse uptake in the scintigraphy was consistent with Grave's disease. She received radioiodine ablation for thyrotoxicosis without the discontinuation of antiviral therapy. At 44 weeks following initiation of her treatment, her liver enzymes became elevated with AST 652, ALT 432, and ALP 413 with normal bilirubin levels [<xref ref-type="fig" rid="F2">Figure 2</xref>].</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Clinical course of pegylated interferon &#x3B1;-2 plus ribavirin therapy for hepatitis C virus infection</p>
        </caption>
        <graphic xlink:href="SJG-17-348-g003"/>
      </fig>
      <p>Serologic evaluation excluded viral hepatitis, the level of a1-antitrypsin was normal and there was no evidence of Wilson's disease or hemochromatosis. She was not on any prescription or over-the-counter medications that could explain this unusual elevation of liver enzymes.</p>
      <p>Further workup revealed newly elevated anti-mitochondrial and anti-smooth muscle antibodies with normal immunoglobulins. Repeat liver biopsy [<xref ref-type="fig" rid="F3">Figure 3</xref>] revealed a periportal inflammatory lymphoplasmacytic infiltrates and piecemeal necrosis without biliary lesions and interface hepatitis consistent with a diagnosis of AIH [<xref ref-type="table" rid="T2">Table 2</xref>].</p>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Liver biopsy following treatment with pegylated interferon &#x3B1;-2 showing interface hepatitis and lymphocytic infiltrate</p>
        </caption>
        <graphic xlink:href="SJG-17-348-g004"/>
      </fig>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Laboratory findings at the time of elevated transaminases</p>
        </caption>
        <graphic xlink:href="SJG-17-348-g005"/>
      </table-wrap>
      <p>Applying the International Diagnostic Criteria for the Diagnosis of AIH,[<xref ref-type="bibr" rid="ref1">1</xref>] we derived a score of 12; generating an interpretation of &#x201C;probable&#x201D; AIH. She was started on prednisone and azathiopurine with subsequent normalization of transaminases. The pattern of transaminase elevation, positive anti-mitochondrial and anti-smooth muscle antibodies, histologic features and response to prednisone and azathiopurine confirmed the diagnosis of AIH. Multiple hepatitis C virus (HCV) RNA levels remained undetectable.</p>
    </sec>
    <sec sec-type="discussion" id="sec1-2">
      <title>DISCUSSION</title>
      <p>The combination of PEG-IFN and ribavirin is the standard therapy for HCV.[<xref ref-type="bibr" rid="ref2">2</xref>] The immunogenic activity of PEG-IFN may trigger the emergence, exacerbation, or de novo manifestation of a range of autoimmune disorders, including thyroid dysfunction, type 1 diabetes mellitus, immune-mediated thrombocytopenia, hemolytic anemia, psoriasis, rheumatoid arthritis, systemic lupus-like syndromes, autoimmune gastritis, primary biliary cirrhosis, AIH, and sarcoidosis, with their reported prevalence ranging between 4% and 19%.[<xref ref-type="bibr" rid="ref3">3</xref>&#x2013;<xref ref-type="bibr" rid="ref5">5</xref>]</p>
      <p>The occurrence of AIH has been reported in patients receiving IFN for multiple sclerosis,[<xref ref-type="bibr" rid="ref3">3</xref>] chronic myeloid leukemia,[<xref ref-type="bibr" rid="ref4">4</xref>] and more recently in, malignant melanoma.[<xref ref-type="bibr" rid="ref5">5</xref>] In CHC patients, initial case reports of exacerbation of liver disease during treatment with IFN were ascribed to AIH, after being incorrectly diagnosed as viral hepatitis and aggravated by the immunostimulating effects of IFN. However, in a study early last decade, Garc&#xED;a-Buey <italic>et al</italic> reported 7 women out of 144 patients initially diagnosed as true HCV, in whom IFN-&#x3B1; treatment resulted in the aggravation of liver disease, which successfully responded to corticosteroids plus azathiopurine.[<xref ref-type="bibr" rid="ref6">6</xref>] They concluded that in female patients with HCV, a genetic susceptibility to AIH may exist, possibly triggered by immunostimulating effects during interferon therapy.[<xref ref-type="bibr" rid="ref6">6</xref>] Since then there have been sporadic case reports in the english literature [<xref ref-type="table" rid="T3">Table 3</xref>] with biopsy-proven AIH following PEG-IFN treatment, which was successfully managed by steroids or azathiopurine.</p>
      <table-wrap id="T3" position="float">
        <label>Table 3</label>
        <caption>
          <p>Previous case reports of AIH following PEG-IFN therapy reported in the english literature</p>
        </caption>
        <graphic xlink:href="SJG-17-348-g006"/>
      </table-wrap>
      <p>From <xref ref-type="table" rid="T3">Table 3</xref> it is clear that the majority of cases have occurred in females.[<xref ref-type="bibr" rid="ref7">7</xref>&#x2013;<xref ref-type="bibr" rid="ref11">11</xref>] Nearly half of the reported patients, including ours were Caucasian.[<xref ref-type="bibr" rid="ref8">8</xref><xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref12">12</xref>] A majority of the patients (similar to our patient) were suffering from type 1b HCV infections.[<xref ref-type="bibr" rid="ref8">8</xref><xref ref-type="bibr" rid="ref10">10</xref><xref ref-type="bibr" rid="ref12">12</xref>] However, unlike our patient, the rest of the patients were treated with PEG-IFN type 2b. Recently a case of AIH, which developed nearly 2 years after viral clearance with IFN, was reported, signifying the importance of long-term follow-up even after sustained virologic response, at least in those patients with underlying autoimmune diathesis.[<xref ref-type="bibr" rid="ref11">11</xref>] IFN-induced AIH culminated into fulminant hepatitis in two of the reported cases.[<xref ref-type="bibr" rid="ref8">8</xref><xref ref-type="bibr" rid="ref10">10</xref>]</p>
      <p>In general, because of the general attenuation of immune response in HIV subjects, autoimmune diseases were believed to be infrequent. However in 2006, Cazanave reported AIH in HCV-HIV co-infected patient who was treated with IFN.[<xref ref-type="bibr" rid="ref13">13</xref>] Further case reports[<xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref10">10</xref>] confirmed that early initiation of anti-retroviral therapy leads to the preservation of good immune status, thus predisposing HIV-positive patients to autoimmune diseases similar to the general population.[<xref ref-type="bibr" rid="ref9">9</xref>]</p>
      <p>The use of PEG-IFN and ribavirin for HCV recurrence post-liver transplant has also been associated with AIH.[<xref ref-type="bibr" rid="ref12">12</xref><xref ref-type="bibr" rid="ref14">14</xref>] Furthermore, the occurrence of a new type of graft dysfunction in liver-transplanted patients receiving PEG-IFN and ribavirin, not related to rejection but due to de novo AIH has been confirmed by two independent studies.[<xref ref-type="bibr" rid="ref15">15</xref><xref ref-type="bibr" rid="ref16">16</xref>]</p>
      <p>The fascinating spectrum of thyroid disease associated with PEG-IFN therapy has been recently classified into autoimmune interferon-induced thyroiditis (IIT) and non-autoimmune IIT.[<xref ref-type="bibr" rid="ref17">17</xref>] Autoimmune IIT can manifest as a clinical disease, that is, as Grave's disease or Hashimoto's thyroiditis, or as a subclinical disease, that is, the production of thyroid autoantibodies (TAb) without abnormal thyroid functions.[<xref ref-type="bibr" rid="ref17">17</xref>] Non-autoimmune IIT can manifest as destructive thyroiditis or non-autoimmune hypothyroidism.[<xref ref-type="bibr" rid="ref17">17</xref>] The frequency of interferon-induced Grave's disease has been estimated to be around 1%.[<xref ref-type="bibr" rid="ref18">18</xref>] Well-established predisposing factors for the development of IIT include female sex, hepatitis C, higher doses and longer duration of IFN therapy.[<xref ref-type="bibr" rid="ref18">18</xref>] Interestingly, thyroid disease is less likely to develop in patients with chronic hepatitis B infection who are treated with interferon alfa than in those with chronic HCV infection, despite the use of higher doses of interferon alfa for the treatment of hepatitis B virus. This finding suggests that HCV and interferon alfa may have a synergistic role in inducing thyroid disease during antiviral therapy.[<xref ref-type="bibr" rid="ref19">19</xref>] Studies have shown that the risk of hypothyroidism is higher when compared with hyperthyroidism (3.8% vs 2.8%)[<xref ref-type="bibr" rid="ref20">20</xref>] and thyroid dysfunction is more common in females when compared with males (13% vs 3%).[<xref ref-type="bibr" rid="ref20">20</xref>] The time of onset of thyroid dysfunction is extremely variable&#x2014;from 8 to 23 months following commencement of interferon.[<xref ref-type="bibr" rid="ref20">20</xref>] In general, thyrotoxicosis is usually seen earlier than hypothyroidism.[<xref ref-type="bibr" rid="ref18">18</xref>]</p>
      <p>The presence of lichen sclerosis in our patient suggests that she had an underlying autoimmune diathesis. The simultaneous onset of two autoimmune disorders suggests a vigorous triggering of the immune system by pegylated IFN-&#x3B1; in a genetically predisposed individual. HCV infection itself may perpetuate the immune cascade, which leads to autoimmune disease, especially in genetically predisposed subjects. It reflects disturbances in self-tolerance due to the molecular mimicry between viral proteins and autoantigens. IFN plays a vital role in eradicating virally infected hepatocytes, but could also enhance recognition of autoantigens, leading to an increased risk for autoimmune diseases. It stimulates natural killer cells and cytotoxic lymphocytes, by stimulating major histocompatibilty complex class 1 expression, and polarizes the adaptive immune response to Th1 (T helper cells).[<xref ref-type="bibr" rid="ref12">12</xref>] This imbalance toward the Th1- mediated response induced by IFN may be the potential pathogenic mechanism in both Grave's disease and AIH.</p>
      <p>To conclude, AIH, which could lead to fulminant hepatitis, should be considered as one possible reason for an increase of transaminase levels during IFN therapy. A high clinical awareness is recommended in patients with known genetic susceptibility or positive autoimmunity markers prior to or during IFN-&#x3B1; therapy.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> None declared.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alvarez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Bianchi</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Bianchi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Burroughs</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Cancado</surname>
              <given-names>EL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis</article-title>
          <source>J Hepatol</source>
          <year>1999</year>
          <volume>31</volume>
          <fpage>929</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">10580593</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghany</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Strader</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Seeff</surname>
              <given-names>LB</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis, management, and treatment of hepatitis C: An update</article-title>
          <source>Hepatology</source>
          <year>2009</year>
          <volume>49</volume>
          <fpage>1335</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">19330875</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Durelli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bongioanni</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Ferrero</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Oggero</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marzano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rizzetto</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Interferon treatment for multiple sclerosis: Autoimmune complications may be lethal</article-title>
          <source>Neurology</source>
          <year>1998</year>
          <volume>50</volume>
          <fpage>570</fpage>
          <lpage>1</lpage>
          <pub-id pub-id-type="pmid">9484407</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steegmann</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Requena</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a-Buey</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Granados</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fern&#xE1;ndez-Ra&#xF1;ada</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response</article-title>
          <source>Am J Hematol</source>
          <year>1998</year>
          <volume>59</volume>
          <fpage>95</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">9723586</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lebiedz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>August</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Domschke</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>HH</given-names>
            </name>
          </person-group>
          <article-title>Interferon (IFN) for malignant melanoma unmasking an autoimmune hepatitis</article-title>
          <source>Eur J Intern Med</source>
          <year>2009</year>
          <volume>20</volume>
          <fpage>e3</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">19237078</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garc&#xED;a-Buey</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a-Monz&#xF3;n</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Borque</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a-S&#xE1;nchez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Iglesias</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C</article-title>
          <source>Gastroenterology</source>
          <year>1995</year>
          <volume>108</volume>
          <fpage>1770</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">7768382</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xF6;rke</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Erhardt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>H&#xE4;ussinger</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Induction of autoimmune hepatitis by pegylated interferon &#x3B1;-2b in chronic hepatitis C</article-title>
          <source>Clin Gastroenterol Hepatol</source>
          <year>2004</year>
          <volume>2</volume>
          <fpage>A20</fpage>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kogure</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ueno</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fukushima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nagasaki</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kakazu</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment</article-title>
          <source>World J Gastroenterol</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>4394</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">17708618</pub-id>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vispo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Maida</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Barreiro</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Soriano</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C</article-title>
          <source>J Antimicrob Chemother</source>
          <year>2008</year>
          <volume>62</volume>
          <fpage>1470</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">18835807</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coriat</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Podevin</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient</article-title>
          <source>Int J STD AIDS</source>
          <year>2008</year>
          <volume>19</volume>
          <fpage>208</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">18397566</pub-id>
        </element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petropoulou</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Dourakis</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Delladetsima</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Archimandritis</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune hepatitis, 2 years after successful peg-interferon-alpha 2b plus ribavirin treatment in a patient with chronic hepatitis C</article-title>
          <source>Ann Gastroenterol</source>
          <year>2010</year>
          <volume>23</volume>
          <fpage>142</fpage>
          <lpage>5</lpage>
        </element-citation>
      </ref>
      <ref id="ref12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kontorinis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Elhajj</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fiel</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Schiano</surname>
              <given-names>TD</given-names>
            </name>
          </person-group>
          <article-title>Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation</article-title>
          <source>Liver Transpl</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>827</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">16628699</pub-id>
        </element-citation>
      </ref>
      <ref id="ref13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cazanave</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rakotondravelo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Morlat</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Blanco</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonnet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Beylot</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune hepatitis in a HIV-HCV co-infected patient: Diagnostic and therapeutic difficulties</article-title>
          <source>Rev Med Interne</source>
          <year>2006</year>
          <volume>27</volume>
          <fpage>414</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">16545501</pub-id>
        </element-citation>
      </ref>
      <ref id="ref14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cholongitas</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Samonakis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Patch</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Senzolo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burroughs</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Quaglia</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus</article-title>
          <source>Transplantation</source>
          <year>2006</year>
          <volume>81</volume>
          <fpage>488</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">16477242</pub-id>
        </element-citation>
      </ref>
      <ref id="ref15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berardi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lodato</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gramenzi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D&#x2019;Errico</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lenzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bontadini</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: Possible <italic>de novo</italic> autoimmune hepatitis?</article-title>
          <source>Gut</source>
          <year>2007</year>
          <volume>56</volume>
          <fpage>237</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">16798778</pub-id>
        </element-citation>
      </ref>
      <ref id="ref16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Merli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gentili</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giusto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Attili</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Corradini</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Mennini</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: Allo or autoimmune <italic>de novo</italic> hepatitis?</article-title>
          <source>Dig Liver Dis</source>
          <year>2009</year>
          <volume>41</volume>
          <fpage>345</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">19162574</pub-id>
        </element-citation>
      </ref>
      <ref id="ref17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandac</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Chaudhry</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Tomer</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification</article-title>
          <source>Hepatology</source>
          <year>2006</year>
          <volume>43</volume>
          <fpage>661</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">16557537</pub-id>
        </element-citation>
      </ref>
      <ref id="ref18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>AX</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cheung</surname>
              <given-names>NW</given-names>
            </name>
          </person-group>
          <article-title>Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2002</year>
          <volume>56</volume>
          <fpage>793</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">12072050</pub-id>
        </element-citation>
      </ref>
      <ref id="ref19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Soto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Escobar-Jimenez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Vazquez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ocete</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Olea</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy</article-title>
          <source>Arch Intern Med</source>
          <year>1998</year>
          <volume>158</volume>
          <fpage>1445</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">9665354</pub-id>
        </element-citation>
      </ref>
      <ref id="ref20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koh</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Greenspan</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Yeo</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
          <article-title>Interferon-alpha induced thyroid dysfunction: Three clinical presentations and a review of the literature</article-title>
          <source>Thyroid</source>
          <year>1997</year>
          <volume>7</volume>
          <fpage>891</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">9459633</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
